Relation of Improvement in Endothelium-Dependent Flow-Mediated Vasodilation After Rosiglitazone to Changes in Asymmetric Dimethylarginine, Endothelin-1, and C-Reactive Protein in Nondiabetic Patients With the Metabolic Syndrome
- 29 August 2006
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 98 (8), 1057-1062
- https://doi.org/10.1016/j.amjcard.2006.05.027
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Short-Term Pioglitazone Treatment Improves Vascular Function Irrespective of Metabolic Changes in Patients With Type 2 DiabetesJournal of Cardiovascular Pharmacology, 2005
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- Assessing Risk Across the Spectrum of Patients with the Metabolic SyndromeThe American Journal of Cardiology, 2005
- Improvement of Cardiovascular Risk Markers by Pioglitazone Is Independent From Glycemic ControlJournal of the American College of Cardiology, 2005
- C-Reactive Protein: Risk Marker or Mediator in Atherothrombosis?Hypertension, 2004
- Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndromeThe American Journal of Cardiology, 2004
- Prognostic value of endothelial functionThe American Journal of Cardiology, 2003
- Rosiglitazone Improves Insulin Sensitivity and Lowers Blood Pressure in Hypertensive PatientsDiabetes Care, 2003
- Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.Circulation, 2002
- Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein LevelsCirculation, 2001